Abstract
An emerging method for allergen-specific immunotherapy is intralymphatic placement, which only requires three injections with intervals of four weeks. In this review, we summarise available evidence on clinical safety, biological efficacy and therapeutic outcomes. The treatment appears to be safe with only few and mild adverse reactions. The immunological activation profile is comparable to that known for subcutaneous therapy. Clinically, patients experienced fewer symptoms with less medication use with intralymphatic allergen-specific immunotherapy than with other types of immunotherapy. The number of studies is limited, and the studies have important limitations. More phase 3 studies are needed in order to make a conclusion.
| Translated title of the contribution | Intralymphatic allergen-specific immunotherapy |
|---|---|
| Original language | Danish |
| Article number | V09170695 |
| Journal | Ugeskrift for Laeger |
| Volume | 180 |
| Issue number | 22 |
| Number of pages | 4 |
| ISSN | 0041-5782 |
| Publication status | Published - 28 May 2018 |